Knee Osteoarthritis: Hyaluronic Acid Once the Usual Alternatives Are Already Closed Off
The guideline recommends against hyaluronic acid for knee osteoarthritis. A patient whose kidney disease limits NSAIDs and whose one steroid injection barely helped is asking for it anyway.
Frank O., 68, spent thirty years framing houses before scaling back to smaller carpentry jobs a few at a time, taken on his own schedule now rather than a foreman's — work he still does most weeks and has no real interest in giving up, both for the income and, he says plainly, because he wouldn't know what to do with himself otherwise. His right knee has been the problem for about two years, no meaningful trouble on the left, no hip involvement, just a knee that swells after a day on his feet and aches enough at night that he's started sleeping with a pillow under it, which helps some but not enough. Topical diclofenac has helped only a little. A corticosteroid injection four months ago gave him roughly six weeks of real relief before the ache crept back to where it started. A friend from his old crew had a hyaluronic acid injection last year and swears by it, and Frank, who has never been one to ask for much from a doctor's visit, wants to try it.
Two things narrow his real options more than they would for most patients his age. His eGFR of 52 puts him in CKD stage 3a, moderate but real kidney impairment, which makes chronic oral or even regular topical NSAID use something to watch rather than reach for freely — the kind of finding that changes which drugs are still genuinely available to him, not just which ones are preferred. And his one steroid injection already told him something concrete about how much relief that route offers his particular knee: real, but short. The 2019 ACR guideline gives hyaluronic acid a conditional recommendation against in knee osteoarthritis, based on pooled effect sizes its own reviewers found didn't clear a minimal clinically important threshold. But that same guideline's own language allows for injecting it anyway, in the context of shared decision-making, once other alternatives have been tried and found wanting — a description that fits Frank's actual situation more closely than the guideline's headline recommendation alone suggests.
Weighing hyaluronic acid against what else Frank has already tried
Frank isn't the population this guideline was really written to discourage. He can't lean on NSAIDs the way most patients can given his kidney function, and his one steroid injection already told us it buys him about six weeks — useful, but not a durable solution he can build a plan around.
Hyaluronic acid has a genuinely low physical risk profile, which matters more than usual here given how narrow his other options already are. I'd rather offer him something with uncertain-but-plausible benefit than tell him to keep managing on topical diclofenac and acetaminophen alone.
I don't think 'his other options are limited' changes what the trials actually found. The ACR panel reviewed the same pooled data everyone else has and concluded the effect size doesn't reach minimal clinically important improvement — meaning even in patients where it does something, that something is close to what an inert injection produces.
That's a different claim than 'uncertain, so worth trying.' It's closer to 'probably not doing much beyond the injection itself,' which is the same dynamic we'd worry about with a repeat steroid course. Offering it because his other doors are closing risks presenting hope as evidence.
We don't have to resolve whether the pooled trial evidence is right about hyaluronic acid in general to make a reasonable decision for Frank specifically. Give him one injection, and before he gets it, agree together on what would actually count as a meaningful response by a set follow-up date — not 'it feels a little different,' but something closer to the improvement threshold the trials themselves were tested against.
If he clears that bar, we have real, personal evidence worth continuing on. If he doesn't, we've spent one injection finding that out rather than committing him to an ongoing series on the strength of hope alone — and either way, he was part of deciding what would count.
Agreed: a single hyaluronic acid injection, with a follow-up appointment at eight weeks and an explicit, jointly defined threshold for what would count as a real response. Topical diclofenac and acetaminophen continue in the meantime.
The team will discuss a further round, treating his own response as real evidence rather than reopening the guideline debate each time.
No further hyaluronic acid; the conversation moves to flare-based corticosteroid dosing and closer monitoring of his renal function alongside any topical NSAID use.
Not agreed: whether the eight-week threshold itself was set generously enough. The rheumatologist would have preferred a higher bar, closer to what the pivotal trials required to call a response meaningful; the physiatrist argued that matching trial-level thresholds too strictly defeats the purpose of an individualized, bounded trial.